Outlier in fully replicate BE study [Outliers]

posted by Loky do – Egypt, 2021-06-16 00:49 (341 d 08:34 ago) – Posting: # 22414
Views: 1,734

Dear colleagues,

During bioanalysis of a fully replicate BE study for drug known to has a potential for back conversion (clopidogrel), one volunteer shows drug concentrations below LLOQ in 3 phases and only one phase (Reference product) shows very low drug concentration, no probability of not swallowing the tablets (mouth check was assured) what could be the reason of this results :confused:? Knowing that the ISR results for the study is accepted?
Thanks in advance

Complete thread:

UA Flag
Activity
 Admin contact
22,091 posts in 4,630 threads, 1,566 registered users;
online 43 (1 registered, 42 guests [including 30 identified bots]).
Forum time: Monday 09:23 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5